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S230 Poster Session Iallogeneic sibling matched bone marrow transplant in autumn 2005,
after ovarian tissue cryopreservation. The conditioning regimen in-
cluded IV busulfan (12.8 mg/kg total dose), cyclophosphamide
(200 mg/kg total dose) and antilymphocyte globulin. A stable
100% donor chimerism was obtained from D60. An acute grade II
GVHDwas followed by limited chronic GVHD for 7 months. Clin-
ical menopause with amenorrhoea due to premature ovarian failure
occured within the first year post-HSCT. Hormone replacement
with oestro-progestogens was started 6 months after HSCT and
was maintained until ovarian function restoration. In spring 2008,
as the patient had been menopausal for 2.5 years, an orthotopic au-
totransplantation of ovarian cortex was performed in two consecu-
tive laparoscopic procedures, the first one being aimed at inducing
local angiogenesis. One thawed strip of ovarian cortex was fixed in
the ovarian incision, 5 others were deposited in the peritoneal win-
dow. Three days later, 3 thawed cortical strips were fixed into the
left ovary and one into the peritoneal window. Ovarian function re-
covery was evaluated by hormonal levels and follicular development
was observed by ultrasound.
The patient conceived spontaneously in a natural cycle in autumn
2008, and delivered a healthy child in June 2009. This first case re-
port of pregnancy and delivery after ovarian autograft in a patient
treated by HSCT suggests that cryopreservation of ovarian tissue
should be offered prior to HSCT not only to women of childbearing
age but also to prepubertal patients, as primordial follicles are al-
ready present in the post natal ovaries.194
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Background:Nearly 90% of the patients who are alive 2 years af-
ter allogeneic SCT (allo-SCT) will become long term survivors
and the focus of care moves to the long term complications.
Chronic graft-versus-host-disease (cGVHD) has attracted the
most attention, especially non-infectious pulmonary complication
bronchiolitis obliterans (BO). Extracorporeal Photopheresis
(ECP), has been shown to be a promising treatment for cGVHD,
however, only a few case reports are available that examines the ef-
fectiveness of ECP for BO.
Methods:Nine patients received ECP between 7/2008-8/2009 after
median follow-up of 23 months (range 9-93) for symptomatic BO
who failed immunosuppressive therapy and combination with azi-
thromycin, inhaled steroids6montelucast sodium. Records were re-
viewed to determine the impact of ECP on BO in an IRB-approved
study. Patients were treated on a weekly basis with 2 pheresis sessions
a week (3 to 4 weeks) and then decreased to an every 2 to 4 week
interval. (Jagasia et al Biol Blood Marrow Transplant 2009;15:
1288-95).
Results: All except one patient received allo-SCT for hematological
malignancies. Themedian age was 38 years (range 21-54), and 5were
female. Patients received allo-SCT between 1/2002- 6/2008 from
matched related (n5 5) or unrelated donor (n5 4); conditioning
consisted TBI based myeloablative regimens in 7 patients. GVHD
prophylaxis consisted of calcineurin inhibitors and methotraxate or
mycophenolate. Grade II-IV aGVHD occurred in 8 patients, grade
III in 1. All patients experienced cGVHD, 3 patients had 5 organ in-
volvements (median 3, range 1-5). Pre-ECP cGVHD pulmonary
subscale score was 3 in 4 (44%) patients. Median time to BO was
17 months post-transplant (range 5-46). All patients had minimum
of 4 drug regimens prior to ECP (median 5, range 4-6) for BO man-
agement. Median time to ECP following diagnosis of BO was 3
months (range 1-54). Eight of 9 (89%) responded to ECP after a me-
dian of 25 days (range 20-958). One patient who did not qualify as
responder had stabilization in FEV1 but continue to remain symp-
tomatic after 108 day on ECP. Three of 4 patients with pulmonary
cGVHD score of 3 responded to addition of ECP.Conclusion: Our case series shows that addition of ECP to com-
monly used regimen for BO results in faster symptomatic improve-
ment in an otherwise debilitating long term complication after
allo- SCT. A limitation of this study is a small sample size, short fol-
low-up, however impressive clinical response.LEUKEMIA
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The addition of tyrosine kinase inhibitors (TKI) to conventional
ALL therapy has significantly improved outcome for Ph+ patients,
resulting in more patients being able to receive HCT in remission.
Maintenance therapy with TKI following HCT may additionally
improve outcomes. We performed a retrospective chart review on
transplants since 2001 when TKI first became available for use fol-
lowing HCT. From March 2001 through June 2009, 66 patients
with median age 37 years (range 3-61) received an allogeneic HCT
for Ph+ ALL in CR1 (n5 56) or CR2 (n5 10); 28 patients were in
complete molecular remission at time of HCT. Patients received
matched related (n5 30) or matched unrelated (n5 27) peripheral
blood (n5 35), bone marrow (n5 22), or mismatched cord blood
cells (n5 9) following a myeloablative TBI-based (n5 48) or non-
TBI-based (n5 18) transplant conditioning regimen. GVHD pro-
phylaxis was tacrolimus-based. All patients received TKI prior to
HCT. Patients were eligible to receive TKI maintenance following
HCT if they had hematologic recovery defined by an unsupported
platelet count .50,000/uL and absolute neutrophil count .1500/
uL. Forty-seven percent (n5 31) of patients received TKI in the
form of imatinib at median dose 300 mg (range 100-800) initiated
at median of 2 months (range 1-12) following HCT. Median dura-
tion of imatinib use post HCT was 13 months (range 1-91). The
most common reason for treatment discontinuation was physician
preference followed by disease progression. Cytopenias and gastro-
intestinal discomfort were the most common imatinib-related toxic-
ities.With amedian follow-up of 4 years among survivors (range 0.3-
7.7), 2-year overall survival (OS) and progression-free survival (PFS)
were 55% and 50%, respectively. Day 100, 1-year, and 2-year non-
relapse mortality (NRM) rates were 11%, 26%, and 28%, respec-
tively. The cumulative incidence of grade 2-4 and 3-4 acute
GVHD were 48% and 16%, respectively; the incidence of chronic
extensive GVHD was 19%. In univariate analysis, imatinib mainte-
nance led to significantly better OS (HR 0.3, 95% CI 0.1-.8,
p5 0.02) and NRM (HR 0.3, 95%CI 0.1-1.1, p5 0.07). Addition-
ally, age. 40 years and CR2 vs CR1 led to significantly worse OS;
molecular remission did not reach statistical significance. Large,
multicenter trials in Ph+ ALL are in progress to confirm the benefit
of TKI maintenance following HCT.196
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Introduction: As Dendritic cells (DC) are effective conductors of
adaptive and innate immune responses, they are used as cellular ad-
juvant for active immunotherapy. Nevertheless, challenges to this
Poster Session I S231approach have been identified. Recently CD40-activated B cells
(CD40-B) have been studied as complementary antigen presenting
cells. They can be expanded from small amounts of PB at.95% pu-
rity underGMP-like conditions and efficiently prime and expand na-
ı¨ve T cells in vitro. Importantly these cells are available at virtually
unlimited amounts for high-dose, high-frequency vaccination con-
sidered crucial for the control of cancer in vivo.
Methods and Results: For preclinical in vivo testing using high-
dose, repetitive vaccinations with CD40-B we developed a murine
system to study their ability to induce immune responses in vivo.
mCD40B are generated from murine splenocytes by co-culture
with murine CD40-Ligand and addition of IL-4. mCD40B cells
could be expanded more than 6-fold within 14 days and .90% pu-
rity. mCD40B were used to establish a vaccination model to study
induction of tumor- and auto-antigen specific immune responses
as well as toxicity of very-high-dose injections (VHD) in B6 mice.
To determine long-term toxicity mice were vaccinated twice weekly
for 5 weeks using high-doses (310^6  110^8/kg) of mCD40B.
This is about 2-3 log higher than currently used in DC vaccinations
in humans. Acute toxicity was assessed by vaccinatingmice once with
VHD (110^7 3.310^8/kg). There was no difference in survival,
weight and clinical appearance compared to control mice. Histo-
pathological assessment did not reveal any pathologic changes. Mu-
rine Mixed Lymphocyte Reaction was established to investigate the
immune-stimulatory capacity of mCD40B in comparison to mDC
through detection of T cell proliferation in vitro. Immune monitor-
ing by intracellular cytokine staining for IFN-g and assessment of in
vivo cytotoxicity revealed that mCD40B vaccination leads to in-
creased IFN-g production by activated T cells and specific lysis of
CFSE-labelled peptide-pulsed target cells.
Conclusion:Based on these findings thatmCD40B induceT cell re-
sponses in vitro and in vivo we are now developing the optimal
mCD40B vaccination algorithm for preventive and therapeutic
treatment of B16-Melanoma in B6 mice as a next step towards future




(n5 30) MRD (n5 10) CB (n5 20) p value
-year OS
(95%CI)
47% (28%-66%) 50% (19%-80%) 44% (20%-68%) 0.9
-year PFS
(95%CI)
39% (21%57%) 40% (10%-70%) 39% (27%-60%) 0.8
-month TRM
(95%CI)
13% (1%-26%) 20% (0-43%) 10% (0-23%) 0.6197
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT)
USING FLUDARABINE/TREOSULFAN CONDITIONING REGIMEN COM-
PARED WITH BUSULFAN-BASED MYELOABLATIVE AND REDUCED-IN-
TENSITY CONDITIONING IN PATIENTS WITH AML AND MDS; RELATIVE
OUTCOMES DEPEND ON DISEASE STATUS AT SCT
Shimoni, A., Shem-Tov, N., Rand, A., Volchek, Y., Yerushalmi, R.,
Hardan, I., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Allogeneic SCT with both myeloablative (MAC) and reduced-in-
tensity conditioning (RIC) is effective therapy in AML/MDS. How-
ever, the relative merits of each differ in different settings.
Fludarabine/treosulfan (FT) has been reported as an effective regi-
men in AML/MDS with limited toxicity. However, the relative
dose intensity and expected outcomes with FT in the different
SCT settings, compared with Busulfan (Bu)-based regimens, is not
well defined. We analyzed the outcomes of 298 pts with AML/
MDS given SCT from sibling (n5 153) or unrelated (n5 145) do-
nors. Pts meeting standard eligibility criteria forMACwere given iv-
BuCy (n5 81). Pts at high risk for MAC were given fludarabine and
reduced doses of ivBu (6.4 mg/kg, FB2, n5 91), high dose Bu (FB4,
12.8 mg/kg, n5 63) or treosulfan (30-36 gr/m2, n5 63). Non-re-
lapse mortality was 17%,18%,18% and 20% with FB2,FB4,FT
and BuCy, respectively (p5NS). With a median follow-up of 38
months (1-115), estimated 5-yr overall survival (OS) was
36%,33%,43% and 41%, respectively (p5NS). Multivariate analy-
sis (MVA) defined age. 50 [HR 1.5 (1-2.2), p5 0.05)], active dis-
ease at SCT [HR 2.3 (1.6-3.2), p\0.001)] and unrelated donor
[HR 1.5 (1-2.0), p5 0.02)] as risk factors for shorter OS. The condi-
tioning regimen was not predictive.When the analysis was limited to
pts in remission (n5 126), OSwas 51%,43%,58%, and 43%, respec-
tively. MVA identified age. 50 as an adverse factor, while SCT us-
ing FB2 or FT was associated with longer OS [HR 0.3 (0.2-0.7),
p5 0.002)]. When the analysis was limited to pts with active disease
(n5 172), either chemo-refractory (n5 93) or untreated (n5 79),OS was 12%,25%,32%, and 36%, respectively. MVA identified
chemo-refractory disease as the major adverse factor for OS [HR
2.2 (1.5-3.3), p5 0.001)], while SCT using BuCy or FT was associ-
ated with longer OS [HR 0.7 (0.5-1.0), p5 0.06)]. In conclusion,
dose intensity is associated with different outcomes in the different
settings. In pts in remission, outcome is mostly related to SCT tox-
icity resulting in an advantage to less intensive regimens, such as
FB2, while FT shares this characteristic. In pts with active disease,
outcome is dominated by the risk for relapse, leading to advantage
of more intensive regimens, such as BuCy. FT shares this character-
istic mainly in pts with no true chemo-refractoriness and has an ad-
vantage over FB2 in this setting. FT should be considered a reduced
toxicity myeloablative conditioning that is feasible in pts ineligible
for MAC.198
SIMILAR AND PROMISING OUTCOMES IN OLDER AML PATIENTS IN FIRST
COMPLETE REMISSION AFTER REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD AND SIBLING DONOR TRANSPLANTATION
Oran, B., Quing, C., Brunstein, C., Majhail, N., Weisdorf, D. University
of Minnesota, Minneapolis, MN
Background: AML has a worse prognosis in older patients indepen-
dent of karyotype abnormalites at the time of diagnosis. However
this group has not been adequately represented in major trials eval-
uating the role of allogeneic allogeneic hematopoietic stem cell
transplantation (HSCT) in AML. Here we present our results with
allogeneic HSCT in older AML patients in first complete remission
(CR1).
Methods:We retrospectively analyzed 30 consecutive patients$ 55
years who underwent their first HSCTwith a matched related donor
(MRD) or cord blood (CB) at the University of Minnesota for AML
in CR1 between January 1995 and December 2007. Study outcomes
were overall survival (OS), progression free survival (PFS) and trans-
plant related mortality (TRM).
Results: Median age was 60 (range 55-68) years; 8 had evolved
from MDS. Thirteen (43%) patients had intermediate risk (all
with normal karyotype) and 17 (57%) had poor risk karyotype.
Donors were MRD (n5 10) and CB (n5 20). Median time
from diagnosis to HSCT was 4.5 months (range 2.6-14.4). Re-
duced intensity conditioning was used in all cases and 27 of 30
(90%) received total-body irradiation (200 cGy), cyclophospha-
mide and fludarabine. Graft versus host disease (GVHD) prophy-
laxis was cyclosporine and mycophenolate mofetil in 27 of 30
patients (90%).
The median follow-up of survivors was 35.3 months (range 9.4-
62.4 months). The probability of 3-year OS was 50% (95% confi-
dence interval (CI), 19%-80%) for MRD and 44% (95% CI, 20%-
68%) for CB (p5 0.9) (Table 1). The probability of 3-year PFS
was 40% (95%CI, 10%-70%) for MRD and 39% (95% CI, 27%-
60%) for CB (p5 0.8). On univariate analysis, poor risk karyotype
and time to transplantation from diagnosis had no impact on disease
outcomes. Grade II-IV aGVHDwas observed in 9 patients (4 MRD
and 5 CB). Chronic GVHD was documented in 10 patients (33%).
Thirteen patients are alive at last contact. Eight of 13 were in remis-
sion and free of all immunosuppression at a median of 24 months
(range 6-32 months). The primary causes of death were relapse
(MRD5 1, CB5 7), infection (MRD5 1, CB5 3), acute GVHD
(MRD5 2) and others. The 6-month TRM was 20% (95%CI,T
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